A Phase III, Randomized, Placebo-Controlled, Multi-Centre Study Evaluating the Safety, Tolerability and Efficacy of Combination Treatment of BL-8040 and G-GSF as Compared to Placebo and G-CSF for thE MobilizatioN of HematopoiEtic Stem Cells for Autologous TransplantatIon in SubjectS With Multiple Myeloma - The GENESIS Study

Trial Profile

A Phase III, Randomized, Placebo-Controlled, Multi-Centre Study Evaluating the Safety, Tolerability and Efficacy of Combination Treatment of BL-8040 and G-GSF as Compared to Placebo and G-CSF for thE MobilizatioN of HematopoiEtic Stem Cells for Autologous TransplantatIon in SubjectS With Multiple Myeloma - The GENESIS Study

Not yet recruiting
Phase of Trial: Phase III

Latest Information Update: 21 Aug 2017

At a glance

  • Drugs BL 8040 (Primary) ; Granulocyte colony-stimulating factors
  • Indications Multiple myeloma
  • Focus Registrational; Therapeutic Use
  • Acronyms GENESIS
  • Sponsors BioLineRx
  • Most Recent Events

    • 21 Aug 2017 According to a BioLineRx media release, company announced regulatory submissions required to commence this study and expects to commence the study by the end of 2017, following receipt of regulatory approvals..
    • 15 Aug 2017 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top